What is Wedbush's price target for AVTE?

Wedbush's latest stated price target for Aerovate Therapeutics Inc. (AVTE) is $3, from its action on Jun 17, 2024.

What is Wedbush's rating on AVTE?

Wedbush rates AVTE Neutral, a neutral rating, as of Jun 17, 2024.

When did Wedbush last change its view on AVTE?

On Jun 17, 2024, Wedbush downgrades to Neutral from Outperform, price target $41 to $3.

Wedbush AVTE price target and rating history

Aerovate Therapeutics Inc. (AVTE) · Health Care

Wedbush rates Aerovate Therapeutics Inc. (AVTE) Neutral with a $3 price target, as of its latest action on Jun 17, 2024. It has published 3 rating actions on AVTE since July 2021, including 0 upgrades and 1 downgrade.

Current rating: Neutral
Price target: $3
Median target, all firms: Too few
Actions on AVTE: 3

Wedbush price target on AVTE

Wedbush price target on AVTE, each point a stated target, July 2021 to June 2024.

Every Wedbush rating on AVTE

Jun 17, 2024
DowngradeWedbush downgrades to Neutral from Outperform, price target $41 to $3
Sep 19, 2022
ResumeWedbush resumes coverage at Outperform, price target $27
Jul 26, 2021
InitiateWedbush starts coverage at Outperform, price target $23

Questions about Wedbush and AVTE

What is Wedbush's price target for AVTE?: Wedbush's latest stated price target for Aerovate Therapeutics Inc. (AVTE) is $3, from its action on Jun 17, 2024.
What is Wedbush's rating on AVTE?: Wedbush rates AVTE Neutral, a neutral rating, as of Jun 17, 2024.
When did Wedbush last change its view on AVTE?: On Jun 17, 2024, Wedbush downgrades to Neutral from Outperform, price target $41 to $3.

More AVTE rating histories

BTIG4

All Wedbush ratings AVTE news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.